Scientific letter
Role of plasmapheresis in the management of severe amiodarone-induced hyperthyroidism refractory to conventional medical treatment
Papel de la plasmaféresis en el manejo del hipertiroidismo severo inducido por amiodarona y refractario a tratamiento médico convencional
Read
205
Timeswas read the article
56
Total PDF
149
Total HTML
Share statistics
array:24 [ "pii" => "S2530018023001221" "issn" => "25300180" "doi" => "10.1016/j.endien.2023.08.003" "estado" => "S300" "fechaPublicacion" => "2023-09-01" "aid" => "1333" "copyright" => "SEEN and SED" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 3:68-71" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2530016422001756" "issn" => "25300164" "doi" => "10.1016/j.endinu.2022.06.001" "estado" => "S300" "fechaPublicacion" => "2023-09-01" "aid" => "1333" "copyright" => "SEEN y SED" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 3:68-71" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICA</span>" "titulo" => "Papel de la plasmaféresis en el manejo del hipertiroidismo severo inducido por amiodarona y refractario a tratamiento médico convencional" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "68" "paginaFinal" => "71" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Role of plasmapheresis in the management of severe amiodarone-induced hyperthyroidism refractory to conventional medical treatment" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2436 "Ancho" => 3008 "Tamanyo" => 293088 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Respuesta de los niveles circulantes de hormonas tiroideas tras el diagnóstico del hipertiroidismo severo y refractario inducido por amiodarona a 17 sesiones de plasmaféresis.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">d: día; P: plasmaféresis.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Belén García Izquierdo, Macarena Contreras Angulo, Laura Armengod Grao, Álvaro García García, Pedro Iglesias" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Belén" "apellidos" => "García Izquierdo" ] 1 => array:2 [ "nombre" => "Macarena" "apellidos" => "Contreras Angulo" ] 2 => array:2 [ "nombre" => "Laura" "apellidos" => "Armengod Grao" ] 3 => array:2 [ "nombre" => "Álvaro" "apellidos" => "García García" ] 4 => array:2 [ "nombre" => "Pedro" "apellidos" => "Iglesias" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2530018023001221" "doi" => "10.1016/j.endien.2023.08.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018023001221?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001756?idApp=UINPBA00004N" "url" => "/25300164/00000070000000S3/v1_202308140929/S2530016422001756/v1_202308140929/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2530018023001269" "issn" => "25300180" "doi" => "10.1016/j.endien.2022.05.010" "estado" => "S300" "fechaPublicacion" => "2023-09-01" "aid" => "1334" "copyright" => "SEEN and SED" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 3:71-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Refeeding syndrome: What to expect when you’re not expecting" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "71" "paginaFinal" => "73" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Síndrome de realimentación: qué esperar cuando no estás esperando" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Francisca Marques Puga, Patrícia Baptista, Ana Oliveira, Margarida França" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Francisca Marques" "apellidos" => "Puga" ] 1 => array:2 [ "nombre" => "Patrícia" "apellidos" => "Baptista" ] 2 => array:2 [ "nombre" => "Ana" "apellidos" => "Oliveira" ] 3 => array:2 [ "nombre" => "Margarida" "apellidos" => "França" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018023001269?idApp=UINPBA00004N" "url" => "/25300180/00000070000000S3/v2_202311091546/S2530018023001269/v2_202311091546/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S253001802300121X" "issn" => "25300180" "doi" => "10.1016/j.endien.2023.08.002" "estado" => "S300" "fechaPublicacion" => "2023-09-01" "aid" => "1330" "copyright" => "SEEN and SED" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 3:67-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Thyroid angiosarcoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "67" "paginaFinal" => "68" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Angiosarcoma tiroideo" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 386 "Ancho" => 755 "Tamanyo" => 100669 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Immunohistochemical staining: ERG. Tumour invasion of thyroid parenchyma and vessels.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Elena Rodríguez Sosa, Itziar Aznar Ondoño, Águeda De Los Ángeles Caballero Figueroa" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Elena" "apellidos" => "Rodríguez Sosa" ] 1 => array:2 [ "nombre" => "Itziar" "apellidos" => "Aznar Ondoño" ] 2 => array:2 [ "nombre" => "Águeda De Los Ángeles" "apellidos" => "Caballero Figueroa" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2530016422001586" "doi" => "10.1016/j.endinu.2022.05.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001586?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S253001802300121X?idApp=UINPBA00004N" "url" => "/25300180/00000070000000S3/v2_202311091546/S253001802300121X/v2_202311091546/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Role of plasmapheresis in the management of severe amiodarone-induced hyperthyroidism refractory to conventional medical treatment" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "68" "paginaFinal" => "71" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Belén García Izquierdo, Macarena Contreras Angulo, Laura Armengod Grao, Álvaro García García, Pedro Iglesias" "autores" => array:5 [ 0 => array:4 [ "nombre" => "Belén" "apellidos" => "García Izquierdo" "email" => array:1 [ 0 => "belengarciaizquierdo@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Macarena" "apellidos" => "Contreras Angulo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Laura" "apellidos" => "Armengod Grao" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Álvaro" "apellidos" => "García García" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 4 => array:3 [ "nombre" => "Pedro" "apellidos" => "Iglesias" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Endocrinología y Nutrición, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Hematología y Hemoterapia, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Papel de la plasmaféresis en el manejo del hipertiroidismo severo inducido por amiodarona y refractario a tratamiento médico convencional" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2436 "Ancho" => 3008 "Tamanyo" => 313218 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Response of the circulating levels of thyroid hormones after the diagnosis of severe refractory amiodarone-induced hyperthyroidism after 17 sessions of plasmapheresis.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">d: day; P: plasmapheresis.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Amiodarone is a class III antiarrhythmic drug widely used in our setting for the treatment of cardiac arrhythmias. It is a benzofuran derivative with high iodine content, which can have a bearing on thyroid function at different levels (hypophysis, thyroid and peripheral receptors). In many cases, it can modify the circulating concentrations of thyroid hormones and be accompanied by both hypo- and hyperthyroidism, although the majority of patients remain euthyroid.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The first-line treatment of amiodarone-induced hyperthyroidism is fundamentally medical with synthetic antithyroid drugs In the case of Type 1 thyrotoxicosis (iodine induced), or with glucocorticoids in type II (owing to glandular destruction). Other less conventional drugs include potassium perchlorate and cholestyramine.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a> Plasmapheresis has occasionally been used in cases of intolerance to antithyroid drugs, refractory hyperthyroidism, and to achieve euthyroidism prior to thyroidectomy, though clinical experience is scant.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">We present the case of a patient with structural cardiopathy with severe amiodarone-induced hyperthyroidism refractory to medical treatment which required a high number of plasmapheresis cycles prior to definitive treatment with thyroidectomy.</p><p id="par0020" class="elsevierStylePara elsevierViewall">53-year-old male with Arterial hypertension, dyslipidaemia, obesity, sleep apnoea syndrome, and persistent anticoagulated atrial fibrillation, owing to which he had received treatment with amiodarone (200 mg/day) over 3 years, with the suspension thereof in the 2 months prior to admission, at which time it was replaced by bisoprolol.</p><p id="par0025" class="elsevierStylePara elsevierViewall">The patient was admitted for a preferential coronary angiography owing to chest pain with elevated markers of cardiac damage, which turned out to be normal. A study with transthoracic echocardiography was completed, showing a severely dilated right ventricle and data on severe pulmonary hypertension, as well as the existence of a superior sinus venosus atrial septal defect, with indication of non-urgent surgical closure. During admission, a severe overt hyperthyroidism was discovered (TSH < 0.01 μIU/mL, normal range [NR]: 0.35–5.0; Free T4 [FT4] 10.03 ng/dl, NR: 0.7–1.98, and Free T3 [FT3] 9.3 pg/mL, NR: 2.3–4.2) one week before the catheterisation was to be performed, without having previously presented exposure to iodised contrast agents. Clinically, he did not report palpitations, tremor, nervousness, or any other symptom of thyroid hyperfunction. He presented with good blood pressure and heart rate control with beta blockers. A grade 2 goitre, with no nodules was palpable. The thyroid echography showed a normal-sized gland with decreased vascularisation. The thyroid autoimmunity study was negative and the Interleukin-6, normal (<2.7 pg/mL, NR: 0.0–4.4). In light of these findings and suspected amiodarone-induced hyperthyroidism, treatment was started with metimazol (30 mg/day) and prednisone (60 mg/day). During admission, the patient presented increasing serum levels of thyroid hormones, which made it necessary to increase the dose of metimazol (45 mg/day) and prednisone (90 mg/day) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). Acholestyramine (16 g/day) and potassium perchlorate (800 mg/day) were also associated. Despite this and, after supervising the proper adherence to the treatment, after three weeks the severe hyperthyroidism persisted (TSH < 0.01 μIU/mL, FT4 11.92 ng/dl and FT3 9.76 pg/mL) with the diagnosis of severe amiodrone-induced hyperthyroidism refractory to high doses of metimazol, corticosteroids, cholestyramine and potassium perchlorate being established, owing to which total thyroidectomy was proposed as definitive treatment. After discussing the case in a multi-disciplinary session with Cardiac Surgery, Cardiology, Anaesthesia, General Surgery and Endocrinology, it was decided to first perform a total thyroidectomy and, secondly, the closure of the ASD. With the aim of reducing perioperative cardiovascular risk, treatment with plasmapheresis was initiated with the aim of achieving euthyroid status.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">The plasmapheresis sessions consisted of mixed plasma exchanges of albumin/plasma of 1.5 volumes in each session, performed by the Haematology Department using an apheresis machine. By way of complications, the patient presented various episodes of skin rash which required prophylactic antihistamine treatment with each exchange. During the procedure, a slight tendency towards anaemisation was observed (nadir of haemoglobin 11.2 g/dl, NR: 12.0–17.0 g/dl; after the 11th session of plasmapheresis, 13 days after its commencement) which required no treatment. An asymptomatic hypocalcaemia was also observed, despite intravenous supplementation with calcium gluconate (nadir of 7.6 mg/dl; NR: 8.7–10.3 mg/dl). All of these complications were resolved after concluding the plasmapheresis.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Given the difficulty to attain a reduction in circulating thyroid hormones, a total of 17 were performed prior to surgery. At no time was the additional medical treatment suspended, although the dose of prednisone was reduced to 40 mg/day. Serum levels of thyroid hormones were also determined on 5 occasions before and after the session of plasmapheresis, achieving a reduction of their levels in the extraction sample immediately post-plasmapheresis (FT4 pre- vs. post-plasmapheresis 7.89 ± 2.48 vs. 4.58 ± 1.35 ng/dl, <span class="elsevierStyleItalic">P</span> = .009; reduction of 41.9% and FT3 pre- vs. post-plasmapheresis 8.60 ± 2.46 vs. 8,24 ± 2.17 pg/mL, <span class="elsevierStyleItalic">P</span> = .157; reduction of 4.1%), with a further increase on the day after plasmapheresis (FT4 following day 6.73 ± 1.07 ng/dl, <span class="elsevierStyleItalic">P</span> = .001; increase of 46.94% and FT3 following day 8.25 ± 2.15 pg/mL, <span class="elsevierStyleItalic">P</span> = .950; increase of 0.1%).</p><p id="par0040" class="elsevierStylePara elsevierViewall">Finally, total thyroidectomy was performed 40 days after the initial diagnosis of hyperthyroidism, without incident. The thyroid profile prior to surgery was TSH 0.01 μIU/mL, FT4 4.33 ng/dl and FT3 4.95 pg/mL. On the day immediately after, a reduction in the FT4 to 3.88 ng/dl was noted, falling to values of 1.98 ng/dl 3 days after the intervention. Given the absence of post-surgical complications, and the rapid normalisation of the thyroid hormones, the patient was discharged with hormone replacement therapy with 150 µg of levothyroxine a day.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Therapeutic plasma exchange (TPE) Is a treatment rarely used for the control of hyperthyroidism. The Blood Bank (Haematology and Haemotherapy Department) was responsible for its implementation, requiring for the procedure afferent and efferent lines connected to the apheresis equipment. Its usefulness is based on the binding of T3 and T4 to plasma proteins that are eliminated. By decreasing their plasma concentration, the hormonal concentration is reduced (principally T4, with a lower free fraction). Additionally, by using fresh plasma as replacement fluid, these proteins are applied allowing the binding of the free hormone.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Its indication in hyperthyroidism is not clearly established. Some authors consider that TPE could be useful in the thyrotoxic storm, in cases of intolerance or refractoriness to conventional treatments, and as preoperative preparation,<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> its most frequent indication being Graves' disease, followed by amiodarone-Induced hyperthyroidism.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Its complications include bleeding, infection, arterial hypotension, hypocalcaemia and skin reactions. The most serious correspond to disseminated intravascular coagulation or pulmonary thromboembolism, with a mortality <1%.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a> In our patient, all the complications were mild and self-limiting.</p><p id="par0055" class="elsevierStylePara elsevierViewall">Although there are studies in which 4–6 TPE sessions were necessary for normalising thyroid hormones<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,11</span></a> in our case, this rose to 17. The analytical alteration was clearly more pronounced in the other series, with exposure to the iodinated contrast agents of the catheterisation also possibly making control more difficult. After reviewing the literature, this case would seem to be the greatest number of plasmapheresis that have been received before definitive treatment. Moreover, each session significantly reduced the FT4, practically without affecting the FT3; however, this reduction was transient, with a significant increase after 24 h, which justified the repetition of sessions. During the evolution, it was difficult to discern the net effect of the drug therapy and the plasmapheresis in controlling the hyperthyroidism. Although there was no reduction in thyroid hormones until the TPE was started, which could reflect the efficacy of this technique.</p><p id="par0060" class="elsevierStylePara elsevierViewall">In conclusion, plasmapheresis would seem to be an effective alternative in those cases of severe amiodarone-induced hyperthyroidism refractory to conventional medical treatment at maximum doses as preparation for definitive treatment with surgery.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding</span><p id="par0065" class="elsevierStylePara elsevierViewall">The authors declare that no type of funding was received for this research.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conflicts of interest</span><p id="par0070" class="elsevierStylePara elsevierViewall">The authors declare that there are no conflicts of interest in relation to this article.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Conflicts of interest" ] 2 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2436 "Ancho" => 3008 "Tamanyo" => 313218 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Response of the circulating levels of thyroid hormones after the diagnosis of severe refractory amiodarone-induced hyperthyroidism after 17 sessions of plasmapheresis.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">d: day; P: plasmapheresis.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:11 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effects of amiodarone on the thyroid" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E. Martino" 1 => "L. Bartalena" 2 => "F. Bogazzi" 3 => "L. Braverman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Endocrine Rev." "fecha" => "2001" "volumen" => "22" "paginaInicial" => "240" "paginaFinal" => "254" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Repercusiones del tratamiento con amiodarona sobre la función tiroidea y su manejo actual" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "P. Iglesias" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Endocrinol Nutr." "fecha" => "2007" "volumen" => "54" "paginaInicial" => "354" "paginaFinal" => "370" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.S. Bahn" 1 => "H.B. Burch" 2 => "D.S. Cooper" 3 => "J.R. Garber" 4 => "M.C. Greenlee" 5 => "I. Klein" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4158/ep.17.3.456" "Revista" => array:6 [ "tituloSerie" => "Endocr Pract." "fecha" => "2011" "volumen" => "17" "paginaInicial" => "456" "paginaFinal" => "520" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21700562" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nonthionamide drugs for the treatment of hyperthyroidism: from present to future" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N. Suwansaksri" 1 => "L. Preechasuk" 2 => "T. Kunavisarut" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int J Endocrinol." "fecha" => "2018" "volumen" => "2018" "paginaInicial" => "1" "paginaFinal" => "10" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of therapeutic plasmapheresis in patients with hyperthyroidism" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "O. Ozdemir Baser" 1 => "Z. Cetin" 2 => "M. Catak" 3 => "D. Koseoglu" 4 => "D. Berker" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Transfus Apher Sci." "fecha" => "2020" "volumen" => "59" "paginaInicial" => "1" "paginaFinal" => "5" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Schwartz" 1 => "A. Padmanabhan" 2 => "N. Aqui" 3 => "R. Balogun" 4 => "L. Connelly-Smith" 5 => "M. Delaney" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jca.21470" "Revista" => array:6 [ "tituloSerie" => "J Clin Apher." "fecha" => "2016" "volumen" => "31" "paginaInicial" => "149" "paginaFinal" => "338" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27322218" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of plasma exchange in the thyroid storm" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C. Muller" 1 => "P. Perrin" 2 => "B. Faller" 3 => "S. Richter" 4 => "F. Chantrel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1744-9987.2011.01003.x" "Revista" => array:6 [ "tituloSerie" => "Ther Apher Dial." "fecha" => "2011" "volumen" => "15" "paginaInicial" => "522" "paginaFinal" => "531" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22107688" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severe hyperthyroidism complicated by agranulocytosis treated with therapeutic plasma exchange: case report and review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "V. Garla" 1 => "K. Kovvuru" 2 => "S. Ahuja" 3 => "V. Palabindala" 4 => "B. Malhotra" 5 => "S. Abdul Salim" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Case Rep Endocrinol." "fecha" => "2018" "volumen" => "2018" "paginaInicial" => "1" "paginaFinal" => "6" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasmaféresis y recambio plasmático" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.R. Barba" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Latinoam Patol Clin Med Lab." "fecha" => "2014" "volumen" => "61" "paginaInicial" => "163" "paginaFinal" => "174" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasmaféresis terapéutica, tipos, técnica e indicaciones en medicina interna" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Restrepo" 1 => "E. Márquez" 2 => "M.F. Sanz- Manizales" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Med Colomb." "fecha" => "2009" "volumen" => "34" "paginaInicial" => "23" "paginaFinal" => "32" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapeutic plasmapheresis in thyrotoxic patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "I. Simsir" 1 => "M. Ozdemir" 2 => "S. Duman" 3 => "M. Erdogan" 4 => "A. Donmez" 5 => "A. Ozgen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12020-018-1661-x" "Revista" => array:6 [ "tituloSerie" => "Endocrine." "fecha" => "2018" "volumen" => "62" "paginaInicial" => "144" "paginaFinal" => "148" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29968224" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25300180/00000070000000S3/v2_202311091546/S2530018023001221/v2_202311091546/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/25300180/00000070000000S3/v2_202311091546/S2530018023001221/v2_202311091546/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018023001221?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 3 | 0 | 3 |
| 2024 October | 9 | 8 | 17 |
| 2024 September | 23 | 4 | 27 |
| 2024 August | 32 | 6 | 38 |
| 2024 July | 20 | 5 | 25 |
| 2024 June | 23 | 5 | 28 |
| 2024 May | 7 | 5 | 12 |
| 2024 April | 20 | 5 | 25 |
| 2024 March | 12 | 18 | 30 |
